On April 18, 2023 Veneno Technologies Co. Ltd. is reported that the company has entered into a joint research agreement with Sumitomo Pharma Co. Ltd., headquartered in Osaka, Japan (Press release, Veneno Technologies, APR 18, 2023, View Source [SID1234630287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is the second such research agreement with a major Japanese research company we have completed this month. We are particularly pleased to be working with researchers at Sumitomo Pharma Co. Ltd." said Kazunori Yoshikawa, President and CEO at Veneno Technologies Co. Ltd.

Under the terms of the agreement, Veneno Technologies [View Source will conduct a program to obtain functional peptides (DRPs) for ion channels targeted by Sumitomo Pharma using Veneno Technologies’ next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection). Work on this project is expected to begin during the 2nd Quarter, 2023.

For inquiries regarding this release, please contact:
Veneno Technologies Co. Ltd.
[email protected]